Hikma Steps Out Of Colchicine Sales Ban Shadow, Maintains 20 Percent Growth Forecast
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA's ban on unapproved colchicine will cut deeply into Jordanian drug maker Hikma's profits and could present some obstacles to the company. However, the London Stock Exchange-listed company vows to maintain an estimated 20 percent growth and expects to continue penetration for its core products in the U.S. generics market
You may also be interested in...
As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
For a company like Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time. The political instability in many countries, especially in Egypt and Tunisia, has hurt Hikma's growth and profitability in the first six months
As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
For a company like Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time. The political instability in many countries, especially in Egypt and Tunisia, has hurt Hikma's growth and profitability in the first six months
As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
For a company like Jordan-based Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time.